CNS Efficacy of Furmonertinib vs Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study
J Thorac Oncol 2022 Aug 03;[EPub Ahead of Print], Y Shi, G Chen, X Wang, Y Liu, L Wu, Y Hao, C Liu, S Zhu, X Zhang, Y Li, J Liu, L Cao, Y Cheng, H Zhao, S Zhang, A Zang, J Cui, J Feng, N Yang, F Liu, Y Jiang, C GuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.